Climb Bio Inc

For the period ended Sep 30, 2024. Filed Nov 12, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 12, 2024

CLYM$11.01+7.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(In thousands, except share and per share amounts)

Assets	September 30, 2024	December 31, 2023
Current assets:
Cash and cash equivalents	$146,175	$93,112
Short-term marketable securities	47,176	13,686
Prepaid expenses and other current assets	4,260	3,457
Total current assets	$197,611	$110,255
Operating lease right-of-use assets	12	199
Long-term marketable securities	24,576	—
Other long-term assets	—	15
Total assets	$222,199	$110,469
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	291	66
Accrued expenses and other current liabilities	3,045	2,433
Accrued expenses, related party	29	—
Operating lease liabilities	58	334
Total current liabilities	$3,423	$2,833
Operating lease liabilities, net of current portion	—	22
Other long-term liabilities	—	15
Total liabilities	$3,423	$2,870
Commitments and contingencies (Note 7)
Stockholders’ equity
Common stock, $0.0001 par value per share, 250,000,000 shares authorized; 67,223,760 and 27,699,446 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively	7	3
Additional paid-in capital	440,028	263,577
Accumulated other comprehensive income (loss)	201	(2)
Accumulated deficit	(221,460)	(155,979)
Total stockholders’ equity	$218,776	$107,599
Total liabilities and stockholders’ equity	$222,199	$110,469

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.